Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839098 | 0.89 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MEN1MITFGAA | |
| SCHEMBL3839195 | 0.89 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MEN1MITFGAA | |
| SCHEMBL3845675 | 0.87 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2MEN1MITFGAA | |
| SCHEMBL17608841 | 0.86 | MAP4K4 (0.41) | ALDH1A1SMN1; SMN2MEN1MITFGAA | |
| SCHEMBL74818 | 0.85 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MEN1MITFGAA | |
| SCHEMBL6289255 | 0.85 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2MEN1MITFGAA | |
| SCHEMBL4569951 | 0.85 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2MEN1MITFGAA | |
| SCHEMBL6289859 | 0.85 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2MEN1MITFGAA | |
| SCHEMBL6290436 | 0.85 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2MEN1MITFGAA | |
| SCHEMBL6290665 | 0.85 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2MEN1MITFGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0850217-B1 | PROCESS FOR THE PREPARATION OF ARYLALKYNYL-N-HYDROXYUREA DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 2000-04-05 | — | — | EP | claimed |
| EP-0850217-A1 | PROCESS FOR THE PREPARATION OF ARYLALKYNYL-N-HYDROXYUREA DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | Abbott Laboratories (US) | 1998-07-01 | — | — | EP | claimed |
| US-5714633-A | Process for the preparation of arylalkynyl-N-hydroxyurea derivatives having lipoxygenase inhibitory activity | ABBOTT LABORATORIES (US) | 1998-02-03 | — | — | US | claimed |
| WO-1997010206-A1 | PROCESS FOR THE PREPARATION OF ARYLALKYNYL-N-HYDROXYUREA DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1997-03-20 | — | — | WO | claimed |
| EP-2616441-B1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9611222-B2 | Pyridine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-09-17 | — | — | US | disclosed |
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-09-17 | — | — | US | disclosed |
| US-9056832-B2 | Pyridine compounds and the users thereof | PURDUE PHARMA L.P. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056832-B2 | Pyridine compounds and the users thereof | PURDUE PHARMA L.P. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| EP-1670757-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
| EP-0850217-B1 | PROCESS FOR THE PREPARATION OF ARYLALKYNYL-N-HYDROXYUREA DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 2000-04-05 | — | — | EP | disclosed |
| EP-0850217-A1 | PROCESS FOR THE PREPARATION OF ARYLALKYNYL-N-HYDROXYUREA DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | Abbott Laboratories (US) | 1998-07-01 | — | — | EP | disclosed |
| US-5714633-A | Process for the preparation of arylalkynyl-N-hydroxyurea derivatives having lipoxygenase inhibitory activity | ABBOTT LABORATORIES (US) | 1998-02-03 | — | — | US | disclosed |
| WO-1997010206-A1 | PROCESS FOR THE PREPARATION OF ARYLALKYNYL-N-HYDROXYUREA DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, CACNA1A, KCNA1 | ALDH1A1 172/4885SMN1; SMN2 522/4885MEN1 1207/4885 |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | TRPV1, CACNA1A, KCNA1 | ALDH1A1 172/4885SMN1; SMN2 522/4885MEN1 1207/4885 |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | ALDH1A1 2211/4885SMN1; SMN2 4724/4885MEN1 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.